QKCMP
A VEGF-mimetic peptide studied in biomaterials work aiming to accelerate endothelialization of small-diameter vascular grafts.
Tag
Cardiovascular
Pages related to Cardiovascular.
GLP‑1 drugs and atrial fibrillation risk
A new observational study links GLP‑1 therapy to lower atrial fibrillation risk even when people do not lose weight, with the strongest signal reported for semaglutide.
A neural clue for GLP-1 drugs’ heart rate bump
In an in vitro rat brainstem-spinal cord setup, exendin-4 increased sympathetic nerve activity and depolarized key neurons, supporting a direct neural route for GLP-1 receptor agonist tachycardia.
SURPASS-CVOT post hoc: broader cardiorenal outcomes favor tirzepatide vs dulaglutide
A post hoc analysis of SURPASS-CVOT expands the endpoint list beyond classic MACE. In patients with type 2 diabetes and established CVD, tirzepatide was associated with fewer composite cardiovascular + kidney events than dulaglutide, with more GI side effects.
A peptide-coated graft and the race to re-create a blood vessel’s inner lining
A 2026 Biomaterials Materials paper tested QKCMP, a short VEGF-mimicking peptide, as a graft-embedded signal meant to accelerate endothelialization. The idea targets a real failure mode, but the evidence is still early and mostly in vitro.
GLP‑1 drugs in type 1 diabetes: the safety signal gets sharper
A huge electronic health record analysis suggests GLP‑1 receptor agonists in type 1 diabetes may be linked to fewer major heart and kidney events without a clear increase in hospitalized DKA—a promising signal that still isn’t a randomized trial.